Alphamab Oncology

In 2025, Alphamab Oncology reported total carbon emissions of approximately 71.9 million kg CO2e. This figure includes Scope 1 emissions of about 8,160 kg CO2e, Scope 2 emissions of approximately 19.3 million kg CO2e, and Scope 3 emissions totalling around 54.8 million kg CO2e, which encompasses categories such as capital goods and purchased goods and services.

The company has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks like the Science Based Targets initiative (SBTi). This lack of formal climate pledges suggests that Alphamab Oncology is currently focusing on reporting its emissions without established goals for reduction.

Overall, while Alphamab Oncology has made strides in transparency regarding its carbon footprint, the absence of reduction commitments highlights an area for potential improvement in its climate strategy.